Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

证券代码：688217 证券简称：睿昂基因 公告编号：2025-034 上海睿昂基因科技股份有限公司(以下简称"公司")全资子公司上海源奇生 物医药科技有限公司于近日收到政府补助资金共人民币 176.29 万元，为与收益 相关的政府补助。 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号—政府补助》的相关规定，公司上述获得的政 府补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处理 以及对公司损益的影响最终以审计机构年度审计确认后的结果为准。敬请投资 者注意投资风险。 特此公告。 上海睿昂基因科技股份有限公司董事会 2025 年 7 月 2 日 上海睿昂基因科技股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获取补助的基本情况 ...

睿昂基因688217 时间: 2025年6月30日星期一 61.47分综合得分 较强 趋势方向 主力成本分析 25.30 元 当日主力成本 24.69 元 5日主力成本 24.10 元 20日主力成本 22.62 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 1 次 短期压力位 23.74 短期支撑位 24.84 中期压力位 23.09 中期支撑位 股价突破短期压力位，短线有望走强； 股价突破中期压力位，中线有望走强 K线形态 ★分离★ 技术面分析 24.63 注意看涨分离和看跌分离 ★多方炮★ 在底部出现有上涨可能，在中间出现有可能是上涨中继，顶部出现是复合见顶信号 资金流数据 2025年06月30日的资金流向数据方面 主力资金净流入129.90万元 占总成交额4% 超大单净流入0.00元 大单净流入129.90万元 散户资金净流入63.61万 关联行业/概念板块 医疗器械 2.13%、体外诊断 1.51%、医疗器械概念 1.62%、基因测序 1.10%等 （以上内容为自选股写手差分机完成，仅作为用户看盘参考，不能作为操作依据。） 风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯 ...

关于对上海睿昂基因科技股份有限公司 2024 年度审计报告出具带强调事项段无保留意见 的专项说明 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 关于对上海睿昂基因科技股份有限公司 2024年度审计报告出具带强调事项段无保留意见 的专项说明 中汇会专[2025]4209号 上海证券交易所: 我们接受委托,依据中国注册会计师审计准则审计了上海睿昂基因科技股份 有限公司(以下简称睿昂基因公司)2024年12月31日的合并及母公司资产负债表, 2024年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有 者权益变动表以及财务报表附注,并于2025年4月16日出具了中汇会审[2025]4206 号带强调事项段无保留意见的审计报告。 表整体的重要性水平为183.77万元。睿昂基因公司近年来经 ...

上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务 所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 法律意见书 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海睿昂基因科技股份有 限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下简称"本 （以下简称"《公司法》"）、 次股东大会"）的有关事宜，根据《中华人民共和国公司法》 《上市公司股东会规则》等法律、法规和其他规范性文件以及《上海睿昂基因科 技股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，出具本法律意见 书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出具该法律 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2025-033 上海睿昂基因科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 20 日 （二） 股东大会召开的地点：上海市奉贤区汇丰西路 1817 弄 147 号睿昂基因会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 33 | | --- | --- | | 普通股股东人数 | 33 | | 2、出席会议的股东所持有的表决权数量 | 17,949,661 | | 普通股股东所持有表决权数量 | 17,949,661 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.5256 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32.5256 | ...

上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2024 年年度股东大会的 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2024 年年度股东大会的 法律意见书 法律意见书 案号：01G20231416 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海睿昂基因科技股份有 限公司（以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下简称"本 次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称《" 公司法》"）、 《上市公司股东会规则》等法律、法规和其他规范性文件以及《上海睿昂基因科 技股份有限公司章程》（以下简称《" 公司章程》"）的有关规定，出具本法律意见 书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原 ...

Core Viewpoint - Shanghai Ruian Gene Technology Co., Ltd. is facing challenges in the biopharmaceutical industry, with a focus on maintaining stability and enhancing governance while navigating a decline in revenue and profit [5][6][10]. Meeting Procedures - The company has established guidelines for the annual shareholder meeting to ensure order and efficiency, requiring attendees to verify their identity and register in advance [1][2]. - Shareholders have the right to speak, inquire, and vote, with specific procedures for raising questions and participating in discussions [3][4]. Financial Performance - In 2024, the company reported a revenue of 242.31 million yuan, a decrease of 6.16% year-on-year, and a net profit attributable to shareholders of -15.76 million yuan, down 298.78% [6][21]. - The core business related to tumors generated revenue of 234.95 million yuan, reflecting a decline of 2.26% [6][21]. Business Developments - The company has made progress in its core business areas, including the addition of 75 new hospital admissions for its products, with specific gains in leukemia and lymphoma product admissions [7][8]. - The company has focused on digital and intelligent upgrades in laboratories, establishing a joint laboratory with Peking University to enhance AI applications in medical technology [8]. Governance and Compliance - The board of directors has adhered to legal and regulatory requirements, ensuring compliance in decision-making and operations, with all submitted proposals approved by shareholders [10][11]. - The supervisory board has conducted oversight on financial operations and internal controls, confirming that the company operates within legal frameworks and maintains financial integrity [18][19]. Future Plans - The company aims to enhance its research and development capabilities, focusing on molecular diagnostics for blood cancers and infectious diseases, with a commitment to affordable precision medicine [13][14]. - Plans for 2025 include advancing clinical projects and improving marketing mechanisms to increase product admissions in hospitals [14][15].

上海睿昂基因科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688217 证券简称：睿昂基因 上海睿昂基因科技股份有限公司 2024 年年度股东大会 会议资料 2025 年 6 月 上海睿昂基因科技股份有限公司 2024 年年度股东大会会议资料 目 录 | 2024 | 年年度股东大会会议须知 | | 3 | | --- | --- | --- | --- | | 2024 | 年年度股东大会会议议程 | | 5 | | 2024 | 年年度股东大会会议议案 | | 7 | | | 议案一《关于 2024 | 年度董事会工作报告的议案》 | 7 | | | 议案二《关于 2024 | 年度监事会工作报告的议案》 14 | | | | 议案三《关于 2024 | 年度独立董事述职报告的议案》 18 | | | | 议案四《关于 2024 | 年度财务决算报告的议案》 | 19 | | | 议案五《关于 2025 | 年度财务预算报告的议案》 | 26 | | | 议案六《关于公司 2024 | 年度利润分配预案的议案》 28 | | | | 议案七《关于<2024 | 年年度报告>及其摘要的议案》 ...

国泰海通证券股份有限公司 关于上海睿昂基因科技股份有限公司 2024 年年度报告的信息披露监管问询函回复的核查意见 上海证券交易所： 贵所下发的《关于上海睿昂基因科技股份有限公司 2024 年年度报告的信息 披露监管问询函》（上证科创公函【2025】0070 号）（以下简称"年报问询函"） 已经收悉。根据年报问询函的要求，国泰海通证券股份有限公司（以下简称"持 续督导机构"）会同上海睿昂基因科技股份有限公司（以下简称"睿昂基因"或 "公司"）及相关中介机构，就年报问询函提及的事项逐项进行了认真讨论、核 查与落实，现就有关事项出具核查意见如下： 问题一：关于试剂业务。年报显示，2024 年，公司营业收入为 24,231 万元， 同比下滑 6.16%。公司主业包括自营试剂、外购制剂、科研服务和检测服务。 自营试剂 2024 年收入为 20,527 万元，同比下滑 2.44%。其中，血液、实体瘤相 关试剂销量同比减少 8.95%、41.43%，传染病、淋巴瘤相关试剂销量同比增长 25.76%、19.18%；公司销售模式包含直销与经销，以直销为主。2022-2024 年， 公司经销收入占比为 3%、23%和 8%，销 ...